FDA pharmacologic class
TNF blockers
7 medicines are in FDA's class of tumor necrosis factor blockers (TNF blockers): adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), adalimumab-adaz (Hyrimoz), certolizumab (Cimzia), golimumab (Simponi) and infliximab-dyyb (Zymfentra). 0 of the 7 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is adalimumab-adaz(cf) pen 40 mg/0.4 ml at $1,587.82 per mL (NADAC).
Which medicines are tnf blockers?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Adalimumab | Amjevita, Humira, Hyrimoz | none listed | $1,587.82 per mL 40 mg/0.4 mL | Yes | No current entry | 1 |
| Etanercept | Enbrel | none listed | $2,084.14 per mL 25 mg/0.5 mL syringe | Yes | No current entry | 0 |
| Infliximab | Remicade, Inflectra, Renflexis | none listed | n/a | Yes | No current entry | 2 |
| Adalimumab-adaz | Hyrimoz | none listed | n/a | No | No current entry | 0 |
| Certolizumab | Cimzia | none listed | $6,094.02 per syringe 2x200 mg/mL syringe kit | Yes | No current entry | 1 |
| Golimumab | Simponi | none listed | $12,890.32 per mL 50 mg/0.5 mL pen injec | Yes | No current entry | 0 |
| Infliximab-dyyb | Zymfentra | none listed | n/a | Yes | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price